Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Update

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the target of a significant decline in short interest in May. As of May 29th, there was short interest totaling 12,411 shares, a decline of 98.9% from the May 14th total of 1,080,288 shares. Based on an average trading volume of 4,135 shares, the short-interest ratio is currently 3.0 days.

Innovent Biologics Stock Down 9.8%

Shares of OTCMKTS IVBXF opened at $9.10 on Wednesday. The company has a 50 day simple moving average of $10.67 and a two-hundred day simple moving average of $10.78. Innovent Biologics has a fifty-two week low of $9.10 and a fifty-two week high of $15.12.

Innovent Biologics Company Profile

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).